Treatment Preference Among People With Cystic Fibrosis

Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis

(2022) Clémence Martin et al.   Journal of Cystic Fibrosis

Digestive outcomes in Cystic fibrosis

(2022) Delphine Ley et al.   Best Practice & Research Clinical Gastroenterology

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?

(2021) Emily Granger et al.   Journal of Cystic Fibrosis

The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery

(2020) Virginie Scotet et al.   Genes

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives

(2020) Lylia Chachoua et al.   Frontiers in Medicine

What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges

(2019) Samare P.I. Huls et al.   VALUE IN HEALTH

Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials

(2019) Gwyneth Davies et al.   Journal of Cystic Fibrosis

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community

(2018) I.L. Hollin et al.   Journal of Cystic Fibrosis

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers

(2017) Nicola J Rowbotham et al.   THORAX

Adherence to therapies in cystic fibrosis: a targeted literature review

(2017) Siva Narayanan et al.   Expert Review of Respiratory Medicine

Cystic fibrosis drug is not cost effective, says NICE

(2016) Anne Gulland   BMJ-British Medical Journal

Cystic fibrosis drug is not cost effective, says NICE

(2016) Anne Gulland   BMJ-British Medical Journal

Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches

(2015) Sarah Acaster et al.   Health and Quality of Life Outcomes

Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis

(2014) Alexandra L. Quittner et al.   CHEST

Reconceptualising the External Validity of Discrete Choice Experiments

(2014) Emily Lancsar et al.   PHARMACOECONOMICS

Integrating evidence on patient preferences in healthcare policy decisions: protocol of the patient-VIP study

(2013) Carmen D Dirksen et al.   Implementation Science

Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes

(2013) Gregory S. Sawicki et al.   Journal of Cystic Fibrosis

Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

(2012) Ben van Hout et al.   VALUE IN HEALTH

Longitudinal association between medication adherence and lung health in people with cystic fibrosis

(2011) Michelle N. Eakin et al.   Journal of Cystic Fibrosis

Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

(2011) John F.P. Bridges et al.   VALUE IN HEALTH

Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis

(2010) Gregory S. Sawicki et al.   PEDIATRIC PULMONOLOGY

High treatment burden in adults with cystic fibrosis: Challenges to disease self-management

(2008) Gregory S. Sawicki et al.   Journal of Cystic Fibrosis